It is well known that nonalcoholic fatty liver disease (NAFLD) is a common disease worldwide because of unhealthy changes in dietary habits. In this study, we determined the effects of Tenebrio molitor Linnaeus, 1758 extract (TML) and Allomyrina dichotoma Linnaeus, 1771 larvae extract (ADL) in cellular and animal models. In vitro, TML and ADL treatments did not cause cytotoxicity, but attenuated the accumulation of lipid in HepG2 cells induced by free fatty acids. In vivo, mice were orally treated with TML and ADL for 10 weeks during high-fat diet feeding. TML and ADL administration significantly reduced the weight of body, liver tissue, and adipose tissue. Serum lipid profiles, hepatic functional parameters, and glucose levels were ameliorated by TML and ADL. Moreover, TML and ADL suppressed increased lipogenesis and inflammation-related makers, and improved antioxidant enzyme activity. In liver tissue, the decreased lipid accumulation by administration of TML and ADL was observed using Oil Red O and Hematoxylin and Eosin staining. Therefore, we suggest that TML and ADL may be having a therapeutic potential and is used to develop a therapeutic agent for NAFLD.
Get full access to this article
View all access options for this article.
References
1.
NakamuraA, TerauchiY: Lessons from mouse models of high-fat diet-induced NAFLD. Int J Mol Sci, 2013; 14:21240–21257.
2.
MaZ, ChuL, LiuH, et al.: Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats. Sci Rep, 2017; 7:44819.
3.
ParkHS, KimMW, ShinES: Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci, 1995; 10:414–421.
4.
KantartzisK, ThamerC, PeterA, et al.: High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut, 2009; 58:1281–1288.
5.
JinYJ, KimKM, HwangS, et al.: Exercise and diet modification in non-obese non-alcoholic fatty liver disease: Analysis of biopsies of living liver donors. J Gastroenterol Hepatol, 2012; 27:1341–1347.
6.
VuppalanchiR, ChalasaniN: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology, 2009; 49:306–317.
7.
Shojaee-MoradieF, BaynesK, PentecostC, et al.: Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism. Diabetologia, 2007; 50:404–413.
8.
HeijdenGJ, WangZJ, ChuZD, et al.: A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents. Obesity, 2010; 18:384–390.
9.
HasegawaT, YonedaM, NakamuraK, MakinoI, TeranoA: Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther, 2001; 15:1667–1672.
10.
HarrisonSA, TorgersonS, HayashiP, WardJ, SchenkerS: Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol, 2003; 98:2485–2490.
11.
MarraF, EfsenE, RomanelliRG, et al.: Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology, 2000; 119:466–478.
12.
GalliA, CrabbDW, CeniE, et al.: Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology, 2002; 122:1924–1940.
13.
LinHZ, YangSQ, ChuckareeC, et al.: Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med, 2000; 6:998–1003.
14.
ZhouG, MyersR, LiY, et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 2001; 108:1167.
15.
GrundySM: National cholesterol education program: Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation, 1994; 89:1329–1445.
16.
NseirW, MograbiJ, GhaliM: Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: Human studies. Dig Dis Sci, 2012; 57:1773–1781.
PaniniRL, FreitasLEL, GuimarãesAM, et al.: Potential use of mealworms as an alternative protein source for Pacific white shrimp: Digestibility and performance. Aquaculture, 2017; 473:115–120.
19.
BukkensSG: The nutritional value of edible insects. Ecol Food Nutr, 1997; 36:287–319.
20.
YounK, KimJY, YeoH, et al.: Fatty acid and volatile oil compositions of Allomyrina dichotoma larvae. Prev Nutr Food Sci, 2012; 17:310–314.
21.
YooJ, HwangJS, GooTW, YunEY: Comparative analysis of nutritional and harmful components in Korean and Chinese mealworms (Tenebrio molitor). J Korean Soc Food Sci Nutr, 2013; 42:249–254.
22.
BaekM, HwangJ, KimM, et al.: Comparative analysis of nutritional components of edible insects registered as novel foods. J Life Sci, 2017; 27:334–338.
23.
LeeHS, LimWC, ChoiJH, et al.: Ameliorating effects of lactic acid-fermented garlic extracts on oleic acid-induced hepatic steatosis. Korean J Food Sci Technol, 2014; 46:762–768.
24.
GhoshS, LeeSM, JungC, MeyerRochowVB: Nutritional composition of five commercial edible insects in South Korea. J Asia Pac Entomol, 2017; 20:686–694.
25.
LeeJH, LeeJ, WhangJ, et al.: Changes in food composition of Tenebrio molitor by life stage. Korean J Food Cook Sci, 2016; 32:656–663.
26.
LeeJH, KimN, LeeDY, LeeCH: Protective effect of selected amino acids and food extracts on ethanol toxicity decrement in rat liver. Korean J Food Sci Technol, 1999; 31:802–808.
27.
SeoM, KimJ, MoonSS, HwangJS, KimMA: Intraventricular administration of Tenebrio molitor larvae extract regulates food intake and body weight in mice with high-fat diet-induced obesity. Nutr Res, 2017; 44:18–26.
28.
KangMS, KimMJ, HanJS, KimAJ: Fatty acid composition and anti-inflammatory effects of the freeze dried Tenebrio molitor larva. Korean J Food Nutr, 2017; 30:251–256.
29.
KimJ, HaqueMN, GooTW, MoonIS: Alleviation of hippocampal endoplasmic reticulum stress by Allomyrina dichotoma larvae extract. Am J Chin Med, 2018; 46:633–650.
30.
YoonYI, ChungMY, HwangJS, et al.: Allomyrina dichotoma (Arthropoda: Insecta) larvae confer resistance to obesity in mice fed a high-fat diet. Nutrients, 2015; 7:1978–1991.
31.
LeeJE, JoDE, LeeAJ, et al.: Hepatoprotective and anticancer activities of Allomyrina dichotoma larvae. J Life Sci, 2015; 25:307–316.
32.
ImAR, YangWK, ParkYC, et al.: Hepatoprotective effects of insect extracts in an animal model of nonalcoholic fatty liver disease. Nutrients, 2018; 10: 735.
33.
FolchJ, LeesM, Sloane StanleyG: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem, 1957; 226:497–509.
34.
KomatsuS: Extraction of nuclear proteins. Methods Mol Biol, 2007; 355:73–77.
35.
JeonSM: Regulation and function of AMPK in physiology and diseases. Exp Mol Med, 2016; 48:e245.
36.
LiangH, ZhangL, WangH, et al.: Inhibitory effect of Gardenoside on free fatty acid-induced steatosis in HepG2 hepatocytes. Int J Mol Sci, 2015; 16:27749–27756.
37.
LudovicoA, GabriellaA, RaffaeleC, NatasaM, FrancescoC: Milk thistle for treatment of nonalcoholic fatty liver disease. Hepat Mon, 2011; 2011:173–177.
38.
ZemelMB, RichardsJ, MilsteadA, CampbellP: Effects of calcium and dairy on body composition and weight loss in African-American adults. Obes Res, 2005; 13:1218–1225.
39.
SohnJH, KimTY: Recent update on pathogenesis of nonalcoholic fatty liver disease. Korean J Med, 2010; 79:461–474.
40.
MehtaR, NeupaneA, WangL, et al.: Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects. BMC Gastroenterol, 2014; 14:208.
41.
ShamsMEE, Al-GayyarMMH, BarakatEAME: Type 2 diabetes mellitus-induced hyperglycemia in patients with NAFLD and normal LFTs: Relationship to lipid profile, oxidative stress and pro-inflammatory cytokines. Sci Pharm, 2011; 79: 623–634.
42.
JeonJH, ParkKG: Definition, pathogenesis, and natural progress of non-alcoholic fatty liver disease. J Korean Diabetes, 2014; 15:65–67.
43.
ChoJK, KangHS, YoonJH: Exercise strategies for the prevention and treatment of non-alcoholic fatty liver disease. Korean J Obes, 2015; 24:190–196.
44.
PerlemuterG, DavitSpraulA, CossonC, et al.: Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease. Liver Int, 2005; 25:946–953.
45.
YouM, MatsumotoM, PacoldCM, ChoWK, CrabbDW: The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology, 2004; 127:1798–1808.
46.
BrowningJD, HortonJD: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest, 2004; 114:147.
47.
AhmedMH, ByrneCD: Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today, 2007; 12:740–747.
48.
ViolletB, GuigasB, LeclercJ, et al.: AMP-activated protein kinase in the regulation of hepatic energy metabolism: From physiology to therapeutic perspectives. Acta Physiol, 2009; 196:81–98.
49.
BrownMS, GoldsteinJL: The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell, 1997; 89:331–340.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
